140 related articles for article (PubMed ID: 25452438)
41. Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer.
Carnevale J; Ashworth A
J Clin Oncol; 2015 Oct; 33(28):3080-1. PubMed ID: 25987697
[No Abstract] [Full Text] [Related]
42. Clinical management of BRCA1 and BRCA2 mutation carriers.
Domchek SM; Armstrong K; Weber BL
Nat Clin Pract Oncol; 2006 Jan; 3(1):2-3. PubMed ID: 16407858
[No Abstract] [Full Text] [Related]
43. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
44. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
45. Pharmacoprevention for hereditary breast and ovarian cancer.
Cazzaniga M; Bonanni B
Minerva Ginecol; 2016 Oct; 68(5):517-35. PubMed ID: 26928419
[TBL] [Abstract][Full Text] [Related]
46. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Dougherty BA; Lai Z; Hodgson DR; Orr MCM; Hawryluk M; Sun J; Yelensky R; Spencer SK; Robertson JD; Ho TW; Fielding A; Ledermann JA; Barrett JC
Oncotarget; 2017 Jul; 8(27):43653-43661. PubMed ID: 28525389
[TBL] [Abstract][Full Text] [Related]
47. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
48. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Stebbing J; Ellis P; Tutt A
Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
[No Abstract] [Full Text] [Related]
49. PARP inhibitors: will the new class of drugs match the hype?
Tuma RS
J Natl Cancer Inst; 2009 Sep; 101(18):1230-2. PubMed ID: 19738163
[No Abstract] [Full Text] [Related]
50. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
51. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
Kauff ND
J Clin Oncol; 2008 Jan; 26(1):9-10. PubMed ID: 18165631
[No Abstract] [Full Text] [Related]
52. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
Sahin I; Ararat E; Altundag K
J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
[No Abstract] [Full Text] [Related]
53. Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes.
Zhang L; Fleischut MH; Kohut K; Spencer S; Wong K; Stadler ZK; Kauff ND; Offit K; Robson ME
Clin Genet; 2011 Jul; 80(1):97-8. PubMed ID: 21649643
[No Abstract] [Full Text] [Related]
54. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
Dhawan MS; Bartelink IH; Aggarwal RR; Leng J; Zhang JZ; Pawlowska N; Terranova-Barberio M; Grabowsky JA; Gewitz A; Chien AJ; Moasser M; Kelley RK; Maktabi T; Thomas S; Munster PN
Clin Cancer Res; 2017 Nov; 23(21):6400-6410. PubMed ID: 28790114
[No Abstract] [Full Text] [Related]
55. BRCA-related ovarian carcinoma.
Rubin SC
Cancer; 2003 May; 97(9):2127-9. PubMed ID: 12712461
[No Abstract] [Full Text] [Related]
56. Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model.
Cremin C; Wong N; Buzaglo K; Paradis AJ; Foulkes W
J Clin Oncol; 2002 Sep; 20(18):3936; author reply 3936-7. PubMed ID: 12228218
[No Abstract] [Full Text] [Related]
57. Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer.
Disis ML
JAMA Oncol; 2015 Jun; 1(3):313. PubMed ID: 26181176
[No Abstract] [Full Text] [Related]
58. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
[No Abstract] [Full Text] [Related]
59. Re: Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Taneja SS
J Urol; 2013 Dec; 190(6):2093. PubMed ID: 24209519
[No Abstract] [Full Text] [Related]
60. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]